• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
Infect Immun. Sep 1998; 66(9): 4268–4273.
PMCID: PMC108515

Characterization of Major Surface Glycoprotein Genes of Human Pneumocystis carinii and High-Level Expression of a Conserved Region

Editor: T. R. Kozel


To facilitate studies of Pneumocystis carinii infection in humans, we undertook to better characterize and to express the major surface glycoprotein (MSG) of human P. carinii, an important protein in host-pathogen interactions. Seven MSG genes were cloned from a single isolate by PCR or genomic library screening and were sequenced. The predicted proteins, like rat MSGs, were closely related but unique variants, with a high level of conservation among cysteine residues. A conserved immunodominant region (of approximately 100 amino acids) near the carboxy terminus was expressed at high levels in Escherichia coli and used in Western blot studies. All 49 of the serum samples, which were taken from healthy controls as well as from patients with and without P. carinii pneumonia, were reactive with this peptide by Western blotting, supporting the hypothesis that most adult humans have been infected with P. carinii at some point. This recombinant MSG fragment, which is the first human P. carinii antigen available in large quantities, may be a useful reagent for investigating the epidemiology of P. carinii infection in humans.

Pneumocystis carinii remains an important life-threatening opportunistic pathogen of immunocompromised patients, especially those with human immunodeficiency virus (HIV) infection. The major surface glycoprotein (MSG; also called glycoprotein A) is the most abundant protein expressed on the surface of P. carinii, as assessed by Coomassie blue staining (22, 29, 36), and appears to play a critical role in the pathogenesis of pneumocystosis, possibly by acting as an attachment ligand to lung cells (7, 28, 45). MSG is also a target of both humoral and cellular immune responses by the host (8, 11, 22, 23, 3739). Previously, we reported that multiple genes encode the MSG of rat P. carinii, and we demonstrated that different MSGs can be expressed in the lung of a rat infected with P. carinii (1, 19). Similarly, multiple genes encode the MSG of P. carinii infecting ferrets and mice (13, 14, 44). Additional studies have shown that there is a single genomic site for expression of rat MSG variants (5, 35, 42, 43). These studies suggest that P. carinii has developed an elaborate system for antigenic variation, presumably to evade host defense mechanisms.

Molecular and immunological studies have clearly demonstrated that P. carinii organisms isolated from different host species are distinct organisms and may in fact be separate species (10, 16, 17, 33). While animal models can provide important information about the biology of P. carinii, studies examining human interactions with P. carinii need to use human P. carinii-derived reagents. The cloning of human P. carinii (Pneumocystis carinii f. sp. hominis) MSG genes has recently been reported (9, 34). Since only one full-length sequence was reported, the present study was undertaken to further characterize the P. carinii f. sp. hominis-derived family of MSG genes. In addition, we undertook to express these genes, since P. carinii f. sp. hominis cannot be cultured and there is no reliable source of organisms for purifying large amount of antigens or other biologically relevant proteins.

(This work was presented in part at the 5th International Workshops on Opportunistic Protists and the 5th General Meeting of the European Concerted Action on Pneumocystis Research, September, 1997, Lille, France [31].)


DNA preparation.

DNA was isolated from an autopsy lung sample from an HIV-infected patient with P. carinii pneumonia according to standard methods, by using sodium dodecyl sulfate (SDS) and proteinase K (0.5 μg/ml), followed by phenol-chloroform extraction and ethanol precipitation (3). A genomic library using the same DNA cloned into the XhoI site of the lambda GEM12 vector (Promega, Madison, Wis.) was commercially prepared (Lofstrand Labs Limited, Gaithersburg, Md.).

PCR and subcloning.

Primers to amplify full-length human P. carinii genes were designed on the basis of published data (9). The sense primer, JK151 (5′-TTT CAT ATG GCG CGG GCG GTC AAG CGG CAG-3′), corresponds to nucleotides 153 to 175 of a published MSG sequence (GenBank accession no. L27092), and the antisense primer, JK152 (5′-CTA AAT CAT GAA CGA AAT AAC CAT TGC TAC-3′), is complementary to nucleotides 3215 to 3244. An NdeI site, which substitutes a methionine for the valine of the original sequence, was created at the beginning of JK151 in order to facilitate subcloning and expression. For amplification, 1 μg of genomic DNA was added to a 50-μl reaction mixture containing primers (25 pM each), deoxynucleoside triphosphates (0.2 mM), 5 U of AmpliTaq (Perkin-Elmer), and MgCl2 (2.5 mM). DNA amplification was performed on a Perkin-Elmer Cetus DNA thermal cycler. An initial denaturation cycle (1 min at 96°C) was followed by 36 cycles of denaturation at 95°C for 1 min, annealing at 50°C for 2 min, and extension at 72°C for 2 min, followed by a final extension after the last cycle at 72°C for 10 min.

Primers for amplifying the conserved carboxyl-terminal region of the human P. carinii MSG gene were designed on the basis of the alignment of five new MSG genes as well as the published sequence. The sense primer was JK451 (5′-GAA TTC GAT CTG AAG CCT CTG GAG-3′), and the antisense primer was JK452 (5′-TTC TAG AAA CCC ACT CAT CTT CAA-3′). An EcoRI site was added to the sense primer, and an XbaI site, which encoded an in-frame stop codon, was added to the antisense primer, to facilitate subcloning. One microgram of plasmid DNA was used for PCR amplification under the conditions described above.

PCR amplification products were subjected to electrophoresis in 1% agarose gel in 1× Tris-borate-EDTA buffer; then PCR products were directly subcloned into PCR II (Invitrogen, Carlsbad, Calif.) according to the manufacturer’s instructions.

Southern hybridization and library screening.

For Southern hybridization with a radioactive probe, DNA was treated with restriction enzymes, separated by agarose gel electrophoresis, and transferred to Hybond N+ membranes (Amersham Life Science, Arlington Heights, Ill.) with 0.4 M NaOH. DNA was probed with an approximately 600-bp XbaI fragment of the human P. carinii MSG III gene (9) (a gift from James R. Stringer, University of Cincinnati, Cincinnati, Ohio) that had been labeled with [α-32P]dATP or [α-32P]dCTP by using a random priming kit (Boehringer Mannheim). Filters were prehybridized for 4 h and then hybridized overnight at 55°C in 6× SSPE (1× SSPE is 0.18 M NaCl, 10 mM NaH2PO4, and 1 mM EDTA [pH 7.7])–0.5% SDS and 5× Denhardt’s solution. Blots were washed in 6× SSPE–0.5% SDS at room temperature for 10 min and then in 0.5× SSPE–0.5% SDS at 55°C twice for 30 min each time. The genomic library was screened by using a gel-purified full-length fragment of human P. carinii MSG 11 under the conditions described above. One clone that hybridized strongly to the probe was subcloned into the BamHI site of pBluescript II (Stratagene, La Jolla, Calif.).

Nucleotide sequencing.

Sequencing was performed with an automated sequencer (model 373 or 377; Applied Biosystems, Perkin-Elmer, Foster City, Calif.) either in our laboratory or by contract (San Diego State University, San Diego, Calif.). The nucleotide sequence and deduced amino acid sequence data were analyzed by Factura and AutoAssembler (both from Applied Biosystems), Sequencher (Gene Codes Corp., Ann Arbor, Mich.), MacVector (Scientific Imaging Systems, New Haven, Conn.), ClustalW (40), and GeneWorks (IntelliGenetics, Mountain View, Calif.).

Construction and expression of recombinant human P. carinii MSG.

The full-length human P. carinii MSG 32 gene was inserted into pBlueBacHis2A (Invitrogen) at the EcoRI site for expression in a baculovirus insect cell system. Correct insertion was confirmed by restriction mapping and sequencing. Isolation of recombinant virus, plaque purification, and amplification of high-titer virus stocks were performed according to the manufacturer’s protocols (Invitrogen). PCR amplification with gene-specific primers was used to confirm the presence of the gene in the virus. Sf9 cells were grown at 27°C in SFII-900 medium (GIBCO BRL, Grand Island, N.Y.) with 5% fetal calf serum to a density of 2.0 × 106 cells/ml. Cells were infected at a multiplicity of infection of 5. Seventy-two hours after infection, cells were harvested by centrifugation, washed with phosphate-buffered saline (PBS) supplemented with phenylmethylsulfonyl fluoride (PMSF) (1 mM), and then resuspended in 10 mM Tris-HCl, pH 8, with 1 mM PMSF and sonicated. The cell lysates were analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting.

For expression of a conserved region of the MSG in Escherichia coli, the 306-bp PCR product of this region was ligated in frame into pET28A (Novagen, Inc., Madison, Wis.) at the EcoRI site. pET28A is an expression vector in which a histidine tag precedes the insertion site. Restriction mapping and sequencing were performed to confirm correct insertion. Expression was induced in E. coli BL21(DE3) using 1 mM isopropyl-β-d-thiogalactopyranoside (IPTG). Recombinant protein was solubilized with 6 M urea and purified by affinity chromatography using a nickel column according to the manufacturer’s instructions (Novagen). The sample was eluted with elution buffer without urea, dialyzed by using 0.5× PBS to eliminate imidazole, and lyophilized for storage. Recombinant protein was analyzed by SDS-PAGE and Western blotting.

SDS-PAGE and Western blotting.

SDS-PAGE and Western blotting were performed by standard techniques, as previously described (18). Electrophoresis was carried out in prepoured discontinuous 8 and 14% acrylamide-Tris-glycine gels (Novex, San Diego, Calif.). Proteins were stained with Coomassie blue or transferred to nitrocellulose membranes, following which Western blotting was performed with a variety of antisera by standard techniques (18). Recombinant rat P. carinii MSG GP3 (expressed in a baculovirus system) (24) and purified recombinant β-galactosidase (expressed in the pET28-E. coli system) were used as controls in Western blotting.

Anti-peptide antisera to a peptide specific for MSG 32 (KMYGLFYGSGKEWFKKLLEKIM, corresponding to amino acids 461 to 482) (see Fig. Fig.1)1) and to a conserved human P. carinii MSG epitope contained within the recombinant carboxyl-terminal fragment (TITSTITSKITLTST, corresponding to amino acids 968 to 982 of MSG 32) were commercially generated in rabbits by the multiple antigenic peptide method (27) (Research Genetics, Huntsville, Ala.). Anti-Xpress monoclonal antibody, which detects an epitope tag at the amino terminus of the fusion proteins expressed in pBlueBacHis2A, was purchased from Invitrogen. T7-tag monoclonal antibody, which detects an epitope tag at the amino terminus of the fusion proteins derived from PET28A, was purchased from Novagen.

FIG. 1
Alignment of the deduced amino acid sequences encoded by two of the human P. carinii MSG genes contained in the genomic clone (HMSGp1 and HMSGp3) and the five genes generated by PCR (HMSG11, HMSG14, HMSG32, HMSG33, and HMSG35), together with a published ...

Human serum samples evaluated by immunoblotting included serum samples from both AIDS and non-AIDS patients with and without a history of P. carinii pneumonia as well as healthy individuals. Human serum samples were tested at a dilution of 1:100. Horseradish peroxidase-conjugated goat anti-human immunoglobulin G (IgG), alkaline phosphatase-conjugated goat anti-rabbit IgG and goat anti-mouse IgG (all from GIBCO BRL), or horseradish peroxidase-conjugated goat anti-cat IgG, anti-rat IgG, and anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc. West Grove, Pa.) were used as second antibodies in Western blotting.

Nucleotide sequence accession numbers.

The sequences of the five PCR-generated human P. carinii MSG clones and the 12,792-bp clone from the genomic library have been deposited in GenBank under accession no. AF033208 through AF033212 and AF038556, respectively.


Although the human P. carinii MSG gene has recently been identified, only one full-length clone has been reported (9, 34). Since multiple variant copies of the MSG gene are present in the rat P. carinii genome, and available data support a similar organization in human P. carinii (9, 34), we wanted to obtain sequence information on additional full-length human P. carinii MSG clones in order to better characterize this family of genes. Since in rat P. carinii the 5′ and 3′ ends of the MSG genes are highly conserved, primers based on the published sequences of these regions of the human P. carinii MSG gene (with modifications to facilitate subcloning and expression) were used in an attempt to amplify additional full-length genes. By using DNA isolated from the lung of an AIDS patient with P. carinii pneumonia, a band of the correct size (approximately 3.1 kb) was amplified and subcloned. Five clones that differed in their restriction mapping and hybridization patterns were identified and sequenced (GenBank accession no. AF033208 to AF033212).

All clones encoded MSG variants that were clearly related but differed from each other. The coding regions of the clones varied in length from 3,054 to 3,087 bases, encoding proteins of 1,008 to 1,028 amino acids with predicted molecular sizes of 114 to 117 kDa. When pairs of clones are compared, they are 74 to 91% identical at the nucleotide level and 63 to 88% identical at the amino acid level. Overall, approximately 50% of the amino acids are conserved in all five clones. The clones are more closely related to each other than to rat P. carinii MSG genes. There is approximately 60% identity at the DNA level and 40% identity at the amino acid level between human P. carinii MSG and rat P. carinii MSG GP3.

To obtain additional P. carinii f. sp. hominis MSG sequences, a genomic library was screened with one of these clones, and one clone that hybridized strongly was subcloned and sequenced. This 12,792-bp clone (GenBank accession no. AF038556) contained three full-length MSG sequences and one partial MSG sequence in a head-to-tail tandem arrangement, similar to that previously reported (9, 34). One of the full-length MSG sequences did not have a complete open reading frame due to a frame shift between bases 6290 and 6347. The codon corresponding to a methionine at the beginning of rat P. carinii MSG clones encoded a valine in all the open reading frames, consistent with earlier observations (9, 34).

Figure Figure11 shows an alignment of the predicted proteins encoded by these genes, together with a rat P. carinii MSG sequence. Among the human P. carinii MSG sequences, there is substantial variability downstream of the amino terminus, while the region near the carboxyl terminus is highly conserved. For example, there is 63% identity in the last 100 amino acids among all the genes (excluding the region encoded by the PCR primer), which is about 5 times as high as the conservation among the first 100 amino acids (13% excluding the primer region). Like most known genes of P. carinii, all human P. carinii MSG genes show a strong AT bias, especially in the third position (approximately 70% A or T) (4, 9, 19, 41). As in other MSG molecules, cysteine residues of the human P. carinii MSG molecules are relatively numerous (5.7 to 5.9%) and are highly conserved: 96% of all the cysteine residues present in the human P. carinii MSG clones are conserved in all the clones. In a comparison between human MSG 11 and rat P. carinii MSG clone GP3, 94% of cysteine residues are conserved. The cysteine residues are unevenly distributed in four main regions and often show a pattern of two cysteines separated by six to seven amino acids, similar to the pattern seen in rat P. carinii (19). There is no predictable pattern to the intervening amino acids. All MSG proteins share a highly conserved amino acid domain rich in threonine and serine residues near the carboxyl terminus. Seven to 13 potential N-linked glycosylation sites [NX(S/T)] were observed in the MSGs. A premature stop codon was seen in MSG 32 after residue 1008, most probably due to a PCR artifact resulting in a point mutation; studies using the ligase chain reaction with primers specific for the mutation supported this conclusion (data not shown).

Because a major goal of these studies was to produce reagents derived from P. carinii f. sp. hominis that could be used to investigate immune responses to human P. carinii, a major effort was made to express a full-length P. carinii f. sp. hominis MSG gene at a high level. By using a baculovirus-insect cell system, a nearly full-length clone, MSG 32 (which contains the premature stop codon), was expressed. A time course showed that maximal expression occurred after 60 to 72 h of infection. The identity of the recombinant protein was confirmed by Western blotting using both an antibody against a peptide tag present in the vector and an antipeptide antibody raised against a peptide specific for MSG 32 (Fig. (Fig.2).2). No reactivity was seen when Sf9 cells alone or recombinant baculovirus-derived rat MSG GP3 was used as the target. The multiple bands seen in the Western blots, especially when the MSG-specific antipeptide antibody was used, likely represent protein degradation products, or possibly modification of the recombinant protein.

FIG. 2
Immunoblots of recombinant nearly full-length human P. carinii MSG 32 expressed in a baculovirus system. Human P. carinii MSG 32 has a stop codon at amino acid 1010 that is likely a PCR artifact but results in elimination of the hydrophobic tail. For ...

Although rat MSG GP3 could be produced at a high level in a baculovirus system and was easily purified by affinity chromatography using a nickel column (24), prolonged attempts to produce and purify high levels of human P. carinii MSG were unsuccessful. We then focused on expressing a highly conserved region at the carboxyl terminus of human P. carinii MSGs (Fig. (Fig.1).1). Preliminary data obtained by epitope mapping have demonstrated that this region is highly immunogenic for antibody production in both rats and humans (1a), suggesting that a peptide encompassing this region could be used in seroepidemiological studies.

PCR was used to amplify this conserved region without the carboxyl-terminal hydrophobic tail, since this hydrophobic tail could potentially interfere with expression and purification. A fragment of approximately 300 bp was obtained by PCR amplification using primers JK451 and JK452, with MSG 33 as a template. The PCR product was subcloned into pET28A, and expression was induced by culturing in 1 mM IPTG. High-level expression was observed within 2 h (Fig. (Fig.3A);3A); no equivalent band was seen when pET28A was used without an insert under the same conditions (Fig. (Fig.3B).3B). The presence of a six-histidine sequence in the expressed portion of the vector preceding the insert allowed rapid, one-step purification of the recombinant protein (Fig. (Fig.4).4). Although the yield was variable from experiment to experiment, during a typical study about 7 mg of purified protein was obtained from a 1-liter culture of E. coli. The identity of the protein was confirmed by immunoblotting using both the T7-tag monoclonal antibody and a polyclonal anti-epitope antibody generated in rabbits against an epitope (TITSTITSKITLTST) contained within the recombinant carboxyl-terminal fragment (Fig. (Fig.5A).5A). No reactivity was seen with preimmune rabbit serum, with uninduced E. coli extracts (data not shown), or with the second antibody alone (Fig. (Fig.5C).5C).

FIG. 3
Time course of expression of a conserved region of human P. carinii MSG 33, as evaluated by SDS-PAGE (14% gel) and Coomassie blue staining. (A) Expression of recombinant protein (arrow) at different time points after induction with IPTG (1 mM). ...
FIG. 4
Purification of a conserved region of human P. carinii MSG 33 (arrow). Lane 1, whole E. coli extract following a 2-h induction with IPTG (1 mM) and solubilization in binding buffer containing 6 M urea; lane 2, flowthrough after binding of the recombinant ...
FIG. 5
Immunoblots with a recombinant conserved human P. carinii MSG peptide. (A) Lane 1, reactivity of the T7-tag monoclonal antibody, which reacts with a pET28A vector-derived epitope that precedes the MSG peptide (arrow); lane 2, reactivity with a polyclonal ...

To evaluate the utility of this recombinant peptide as a tool for investigating the seroepidemiology of P. carinii infection, immunoblotting studies with a variety of human serum samples (diluted 1:100) were undertaken. Samples included those from 11 immunosuppressed patients with recent or acute P. carinii pneumonia but without HIV infection, from 5 patients with HIV infection and P. carinii pneumonia, from 17 patients with HIV infection but without P. carinii pneumonia, from 3 patients with neither HIV infection nor P. carinii pneumonia, and from 13 healthy laboratory workers. All 49 samples reacted by immunoblotting with the recombinant peptide (Fig. (Fig.5B).5B). Because the recombinant peptide included a region that was vector derived, a subset of four samples was simultaneously evaluated by immunoblotting for reactivity with recombinant β-galactosidase expressed in the same vector. None of the samples reacted with the recombinant β-galactosidase (data not shown), demonstrating that the reactivity seen was against the P. carinii-derived peptide region. In addition, little or no reactivity was seen when rat, mouse, or cat serum was used (Fig. (Fig.55C).


In recent years, a great deal of interest has focused on the MSG of P. carinii, since it is both a likely virulence factor and a target of host immune responses (7, 8, 11, 22, 23, 28, 3739, 45). Studies of human P. carinii infection ideally require P. carinii f. sp. hominis-derived reagents, given the high level of variation among homologous genes, including the MSG genes, isolated from different host-specific strains of the organism. We thus undertook to better characterize and express P. carinii f. sp. hominis MSG variants. A previous study reported that, like rat and ferret P. carinii MSG, human P. carinii MSG is also encoded by a family of related genes (1, 9, 19, 34, 44). The present study extends these observations by providing data on additional complete MSG genes.

This study has further confirmed that the structure of human P. carinii MSG is similar to those of the MSGs of P. carinii organisms infecting other hosts, with a high degree of variation near the amino terminus and a high level of conservation near the carboxyl terminus. The serine- and threonine-rich domains seen in rat P. carinii are also present in human P. carinii MSGs, but, as previously noted (9), a proline- and glycine-rich region present in rat P. carinii MSGs is absent from human P. carinii MSGs (Fig. (Fig.1).1). In addition, cysteine residues are highly conserved not only among human P. carinii MSGs but between human and rat P. carinii MSGs. It is probable that these cysteines play an important role in determining the tertiary structure of MSG; thus, conservation of these residues suggests that, despite substantial variation in the predicted primary amino acid sequences, all MSGs have similar tertiary structures. This would be consistent with a similar function for all MSGs despite the sequence variability.

The genomic clone confirms that valine rather than methionine is present at the beginning of the MSG open reading frame in a position homologous to that of the methionine in rat P. carinii MSGs. While this was initially interpreted as potentially representing an alternative translation initiation codon (9), recent studies with rat P. carinii have shown that the MSG variant genes are inserted in frame downstream of a leader sequence encoded in the single expression site for these genes (5, 35, 42, 43). Mouse P. carinii MSG cDNA clones also appear to encode a similar leader sequence (13). Thus, the translation initiation codon for P. carinii f. sp. hominis MSG genes is presumably a methionine present at the beginning of this leader sequence, which has not yet been characterized. The genomic sequences have confirmed that the Lys-Arg sequence located 5 positions downstream of the valine is conserved in all P. carinii f. sp. hominis MSGs identified to date. This is consistent with the postulated role of this sequence in all P. carinii strains as a target for cleavage by P. carinii kexin (20, 31), which would eliminate the conserved leader from the surface-expressed form of the MSG variants and maximize antigenic variation.

A second major focus of the present study was to express P. carinii f. sp. hominis MSG at a high level in order to provide reagents for studies of human-P. carinii interaction. While a nearly full-length MSG could be expressed in a baculovirus system, we were unable to induce high-level expression, perhaps because of the high proportion of cysteine residues. The presence of a hydrophobic tail may also interfere with expression, as the only full-length clone we were able to express had a premature stop codon prior to this hydrophobic tail.

However, an immunodominant region at the carboxyl terminus (minus the hydrophobic tail) could be expressed at a high level in a bacterial expression system and was easily purified via a six-histidine tag encoded in the vector. By immunoblotting, all 49 human serum samples tested were reactive with this peptide, regardless of their immune status or history of P. carinii pneumonia, supporting the hypothesis that most humans have been exposed to P. carinii at some point (22, 25). Reactivity was not seen with a control protein expressed in the same plasmid. Little or no reactivity was seen when serum from a rat, mouse, or cat was used (Fig. (Fig.5),5), suggesting that the responses are specific for human P. carinii and not a result of exposure to an irrelevant environmental antigen. The low level of reactivity seen with the rat serum may also represent cross-reactivity due to prior exposure to P. carinii f. sp. carinii, given that there is homology between rat and human P. carinii MSG sequences in this region (Fig. (Fig.11).

Previous studies evaluating the serological responses of humans to P. carinii have relied on a variety of assays, including fixed-tissue staining, immunofluorescence, enzyme-linked immunosorbent assays, and Western blotting using either rat or human P. carinii organisms or purified proteins as antigens. Results have been conflicting: some studies have shown that a high proportion of humans have serological reactivity with P. carinii antigens, while others have shown low response rates (2, 6, 15, 2123, 26, 32). In previous studies using purified human P. carinii MSG, we noted response rates of 34 to 66% (23). Western blot studies have shown similar rates of reactivity with MSG (26). Differences between these previous results and the present results may be related to the sensitivity of the techniques, the integrity of the human P. carinii antigens used in prior studies (given that the antigens were derived from autopsy samples), or other methodological differences. Thus, this peptide is the first human P. carinii-specific antigen available in sufficient quantities for large-scale studies. The preliminary studies reported here suggest that this antigen may be a useful tool for seroepidemiologic investigation of P. carinii infection in humans, for example, to identify the period of seroconversion in humans, although more extensive studies are needed to verify this utility.

While antibodies appear to play a role in clearing P. carinii, T-cell response appears to be of primary importance in clearance (12, 30). Additional studies are needed to determine if this recombinant fragment contains T-cell epitopes in addition to B-cell epitopes. If so, evaluation of proliferative responses to this antigen may provide useful prognostic information, for example, about the risks of developing P. carinii pneumonia during HIV infection. In addition, given that it is a highly conserved region of the highly variable MSG, this recombinant peptide is a good candidate for evaluation as a vaccine for the prevention of P. carinii pneumonia.


We thank James Stringer and Saundra Stringer for providing a fragment of a human P. carinii MSG gene.


1. Angus C W, Tu A, Vogel P, Qin M, Kovacs J A. Expression of variants of the major surface glycoprotein of Pneumocystis carinii. J Exp Med. 1996;183:1229–1234. [PMC free article] [PubMed]
1a. Angus, C. W., et al. Unpublished data.
2. Burns S M, Read J A, Yap P L, Brettle R P. Reduced concentrations of IgG antibodies to Pneumocystis carinii in HIV-infected patients during active Pneumocystis carinii infection and the possibility of passive immunisation. J Infect. 1990;20:33–39. [PubMed]
3. Davis L G, Dibne M D, Battey J F. Basic methods in molecular biology. New York, N.Y: Elsevier; 1986.
4. Edman J C, Edman U, Cao M, Lundgren B, Kovacs J A, Santi D V. Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene. Proc Natl Acad Sci USA. 1989;86:8625–8629. [PMC free article] [PubMed]
5. Edman J C, Hatton T W, Nam M, Turner R, Mei Q, Angus C W, Kovacs J A. A single expression site with a conserved leader sequence regulates variation of expression of the Pneumocystis carinii family of major surface glycoprotein genes. DNA Cell Biol. 1996;15:989–999. [PubMed]
6. Elvin K, Bjorkman A, Heurlin N, Eriksson B M, Barkholt L, Linder E. Seroreactivity to Pneumocystis carinii in patients with AIDS versus other immunosuppressed patients. Scand J Infect Dis. 1994;26:33–40. [PubMed]
7. Ezekowitz R A B, Williams D J, Koziel H, Armstrong M Y K, Warner A, Richards F F, Rose R M. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature. 1991;351:155–158. [PubMed]
8. Fisher D J, Gigliotti F, Zauderer M, Harmsen A G. Specific T-cell response to a Pneumocystis carinii surface glycoprotein (gp120) after immunization and natural infection. Infect Immun. 1991;59:3372–3376. [PMC free article] [PubMed]
9. Garbe T R, Stringer J R. Molecular characterization of clustered variants of genes encoding major surface antigens of human Pneumocystis carinii. Infect Immun. 1994;62:3092–3101. [PMC free article] [PubMed]
10. Gigliotti F. Host species-specific antigen variation of a mannosylated surface glycoprotein of Pneumocystis carinii. J Infect Dis. 1992;165:329–336. [PubMed]
11. Gigliotti F, Garvy B A, Harmsen A G. Antibody-mediated shift in the profile of glycoprotein A phenotypes observed in a mouse model of Pneumocystis carinii pneumonia. Infect Immun. 1996;64:1892–1899. [PMC free article] [PubMed]
12. Gigliotti F, Hughes W T. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Investig. 1988;81:1666–1668. [PMC free article] [PubMed]
13. Haidaris C G, Medzihradsky O F, Gigliotti F, Simpson-Haidaris P J. Molecular characterization of mouse Pneumocystis carinii surface glycoprotein A. DNA Res. 1998;5:77–85. [PubMed]
14. Haidaris P J, Wright T W, Gigliotti F, Haidaris C G. Expression and characterization of a cDNA clone encoding an immunodominant surface glycoprotein of Pneumocystis carinii. J Infect Dis. 1992;166:1113–1123. [PubMed]
15. Hofmann B, Odum N, Platz P, Ryder L P, Svejgaard A, Nielsen P B, Holten Andersen W, Gerstoft J, Nielsen J O, Mojon M. Humoral responses to Pneumocystis carinii in patients with acquired immunodeficiency syndrome and in immunocompromised homosexual men. J Infect Dis. 1985;152:838–840. [PubMed]
16. Keely S, Pai H J, Baughman R, Sidman C, Sunkin S M, Stringer J R, Stringer S L. Pneumocystis species inferred from analysis of multiple genes. J Eukaryot Microbiol. 1994;41:94S. [PubMed]
17. Kovacs J A, Halpern J L, Lundgren B, Swan J C, Parrillo J E, Masur H. Monoclonal antibodies to Pneumocystis carinii: identification of specific antigens and characterization of antigenic differences between rat and human isolates. J Infect Dis. 1989;159:60–70. [PubMed]
18. Kovacs J A, Halpern J L, Swan J C, Moss J, Parrillo J E, Masur H. Identification of antigens and antibodies specific for Pneumocystis carinii. J Immunol. 1988;140:2023–2031. [PubMed]
19. Kovacs J A, Powell F, Edman J C, Lundgren B, Martinez A, Drew B, Angus C W. Multiple genes encode the major surface glycoprotein of Pneumocystis carinii. J Biol Chem. 1993;268:6034–6040. [PubMed]
20. Lugli E B, Allen A G, Wakefield A E. A Pneumocystis carinii multi-gene family with homology to subtilisin-like serine proteases. Microbiology. 1997;143:2223–2236. [PubMed]
21. Lundgren B, Lebech M, Lind K, Nielsen J O, Lundgren J D. Antibody response to a major human Pneumocystis carinii surface antigen in patients without evidence of immunosuppression and in patients with suspected atypical pneumonia. Eur J Clin Microbiol Infect Dis. 1993;12:105–109. [PubMed]
22. Lundgren B, Lipschik G Y, Kovacs J A. Purification and characterization of a major human Pneumocystis carinii surface antigen. J Clin Investig. 1991;87:163–170. [PMC free article] [PubMed]
23. Lundgren B, Lundgren J D, Nielsen T, Mathiesen L, Nielsen J O, Kovacs J A. Antibody responses to a major Pneumocystis carinii antigen in human immunodeficiency virus-infected patients with and without P. carinii pneumonia. J Infect Dis. 1992;165:1151–1155. [PubMed]
24. Mei Q, Kovacs J A, Hildebrand B, Angus C W. Expression of the major surface glycoprotein of rat-derived Pneumocystis carinii by recombinant baculovirus. J Eukaryot Microbiol. 1996;43:31S. [PubMed]
25. Meuwissen J H, Tauber I, Leeuwenberg A D, Beckers P J, Sieben M. Parasitologic and serologic observations of infection with Pneumocystis in humans. J Infect Dis. 1977;136:43–49. [PubMed]
26. Peglow S L, Smulian A G, Linke M J, Pogue C L, Nurre S, Crisler J, Phair J, Gold J W M, Armstrong D, Walzer P D. Serologic responses to Pneumocystis carinii antigens in health and disease. J Infect Dis. 1990;161:296–306. [PubMed]
27. Posnett D N, McGrath H, Tam J P. A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor beta-chain. J Biol Chem. 1988;263:1719–1725. [PubMed]
28. Pottratz S T, Paulsrud J, Smith J S, Martin W J., II Pneumocystis carinii attachment to cultured lung cells by pneumocystis gp120, a fibronectin binding protein. J Clin Investig. 1991;88:403–407. [PMC free article] [PubMed]
29. Radding J A, Armstrong M Y K, Ullu E, Richards F F. Identification and isolation of a major cell surface glycoprotein of Pneumocystis carinii. Infect Immun. 1989;57:2149–2157. [PMC free article] [PubMed]
30. Roths J B, Sidman C L. Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice. J Clin Investig. 1992;90:673–678. [PMC free article] [PubMed]
31. Russian D A, Andrawis-Sorial V, Edman J C, Vogel P, Turner R E, Klivington D L, Angus C W, Kovacs J A. Abstracts of the 5th International Workshops on Opportunistic Protists and 5th General Meeting of the European Concerted Action on Pneumocystis Research. 1997. Identification and characterization of novel surface expressed serine protease variants encoded by a multicopy gene family in Pneumocystis carinii, abstr. O31.
32. Smulian A G, Sullivan D W, Linke M J, Halsey N A, Quinn T C, MacPhail A P, Hernandez Avila M A, Hong S T, Walzer P D. Geographic variation in the humoral response to Pneumocystis carinii. J Infect Dis. 1993;167:1243–1247. [PubMed]
33. Stringer J R. The identity of Pneumocystis carinii: not a single protozoan, but a diverse group of exotic fungi. Infect Agents Dis. 1993;2:109–117. [PubMed]
34. Stringer S L, Garbe T, Sunkin S M, Stringer J R. Genes encoding antigenic surface glycoproteins in Pneumocystis from humans. J Eukaryot Microbiol. 1993;40:821–826. [PubMed]
35. Sunkin S M, Stringer J R. Translocation of surface antigen genes to a unique telomeric expression site in Pneumocystis carinii. Mol Microbiol. 1996;19:283–295. [PubMed]
36. Tanabe K, Takasaki S, Watanabe J, Kobata A, Egawa K, Nakamura Y. Glycoproteins composed of major surface immunodeterminants of Pneumocystis carinii. Infect Immun. 1989;57:1363–1368. [PMC free article] [PubMed]
37. Theus S A, Andrews R P, Linke M J, Walzer P D. Characterization of rat CD4 T cell clones specific for the major surface glycoprotein of Pneumocystis carinii. J Eukaryot Microbiol. 1997;44:96–100. [PubMed]
38. Theus S A, Andrews R P, Steele P, Walzer P D. Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat. J Clin Investig. 1995;95:2587–2593. [PMC free article] [PubMed]
39. Theus S A, Linke M J, Andrews R P, Walzer P D. Proliferative and cytokine responses to a major surface glycoprotein of Pneumocystis carinii. Infect Immun. 1993;61:4703–4709. [PMC free article] [PubMed]
40. Thompson J D, Higgins D G, Gibson T J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673–4680. [PMC free article] [PubMed]
41. Wada M, Kitada K, Saito M, Egawa K, Nakamura Y. cDNA sequence diversity and genomic clusters of major surface glycoprotein genes of Pneumocystis carinii. J Infect Dis. 1993;168:979–985. [PubMed]
42. Wada M, Nakamura Y. Unique telomeric expression site of major-surface-glycoprotein genes of Pneumocystis carinii. DNA Res. 1996;3:55–64. [PubMed]
43. Wada M, Sunkin S M, Stringer J R, Nakamura Y. Antigenic variation by positional control of major surface glycoprotein gene expression in Pneumocystis carinii. J Infect Dis. 1995;171:1563–1568. [PubMed]
44. Wright T W, Bissoondial T Y, Haidaris C G, Gigliotti F, Haidaris P J. Isoform diversity and tandem duplication of the glycoprotein A gene in ferret Pneumocystis carinii. DNA Res. 1995;2:77–88. [PubMed]
45. Zimmerman P E, Voelker D R, McCormack F X, Paulsrud J R, Martin W J., II 120-kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein. A J Clin Investig. 1992;89:143–149. [PMC free article] [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...